Artgen Biotech bought out part of Genetico shares

Genetico notes that part of the funds raised will go “to developing a portfolio of gene therapy drugs for the treatment of orphan diseases.”

The decision to increase the authorized capital through the placement of additional ordinary shares by closed subscription was made by Genetico shareholders back in October 2024. The cost of one share was 34 rubles.

In December 2024, the developer of Betuvax vaccines (part of PJSC Artgen Biotech, formerly known as the Human Stem Cell Institute) attracted 100 million rubles in venture capital investments during a closed private placement. The funds will be used to conduct preclinical and clinical trials of a vaccine against cat allergies, as well as to develop vaccines against human papillomavirus and rotavirus.

At the end of June 2025, it became known that Artgen Biotech would create the Artgen Seed Fund, aimed at supporting early-stage startups in the field of artificial intelligence, medical decision support systems, digital health, anti-aging, personalized medicine and diagnostics, gene therapy, oncology and neuroscience. The fund's volume over three years will be up to 150 million rubles. It is expected that it will be replenished, including by attracting partner investors.